First-in-Man Evaluation of ¹²⁴I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment.

ABSTRACT:

Purpose

PGN650 is a F(ab')₂ antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy. PGN650 was labeled with ¹²⁴I to create a positron emission tomography (PET) agent as an in vivo biomarker for tumor microenvironment and response to therapy. In this phase 0 study, we evaluated the pharmacokinetics, safety, radiation dosimetry, and tumor targeting of this tracer in a cohort of patients with cancer.

Methods

Eleven patients with known solid tumors received approximately 140 MBq (3.8 mCi) ¹²⁴I-PGN650 intravenously and underwent positron emission tomography-computed tomography (PET/CT) approximate

SUBMITTER: Laforest R 

PROVIDER: S-EPMC5648081 | biostudies-literature | 2017 Jan-Dec

REPOSITORIES: biostudies-literature